Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
177Lu-octreotate
- Development stage
- Unknown
- Lead developer
- CHU de Québec-Université Laval
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous, Intra-arterial
01
Overview
177Lu-octreotate is a radiopharmaceutical consisting of the beta-emitting radionuclide lutetium-177 complexed with the somatostatin analogue octreotate via a DOTA chelator. Developed as a personalized peptide receptor radionuclide therapy (P-PRRT) at CHU de Québec-Université Laval, this specific protocol (NCT02754297) utilizes quantitative SPECT/CT-based dosimetry to tailor the administered radioactivity for each patient. The therapy targets somatostatin receptor type 2 (SSTR2), which is highly expressed in neuroendocrine tumors (NETs). Upon binding and internalization, the lutetium-177 delivers localized ionizing radiation, causing DNA damage and apoptosis in tumor cells. The personalized approach aims to maximize the radiation dose delivered to the tumor while maintaining safe radiation limits for critical organs, particularly the kidneys.
- Other names
- lutetium Lu 177 dotatatelutetium-177-octreotatelutetium177-octreotatelutetium 177-octreotate177Lu-DOTATATE177Lu-DOTA-Tyr3-octreotate
02
Targets
SSTR2 (Somatostatin receptor type 2)
Beyond the preview
Go deeper on 177Lu-octreotate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 177Lu-octreotate.